Use of calcium channel blockers and risk of hospitalized gastrointestinal tract bleeding

Robert C. Kaplan, Susan R. Heckbert, Thomas D. Koepsell, Frits R. Rosendaal, Bruce M. Psaty

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Background: We conducted a case-control study of the association between calcium channel blocker use and gastrointestinal (GI) tract bleeding in hypertensive members of a health maintenance organization. Methods: Case patients (n = 174) were treated hypertensive health maintenance organization members hospitalized for GI tract bleeding between January 1992 and December 1994. Case patients were identified using computerized diagnosis codes and were confirmed by medical record review. Control subjects (n = 771) were treated hypertensive members selected from ongoing studies at the health maintenance organization. Computerized pharmacy data and medical records were used to assess medication use and other risk factors for GI tract bleeding. Results: Compared with β-blocker users, calcium channel blocker users had an age-, sex- and calendar year adjusted relative risk (RR) of GI tract bleeding of 2.60 (95% confidence interval [CI], 1.71-3.96). The RR associated with calcium channel-blocker use was 2.05 (95% CI, 1.33-3.17) after further adjustment for number of recent visits, diastolic blood pressure, chronic congestive heart failure, and duration of hypertension. No significant dose- response relationship was observed. Compared with β-blocker users, angiotensin-converting enzyme inhibitor users had an RR of 1.22 (95% CI, 0.75-1.97). Calcium channel blocker use tended to be more strongly associated with risk of lower GI tract bleeding (RR, 2.56; 95% CI, 1.08-6.05) than with risk of upper GI tract bleeding (RR, 1.54; 95% CI, 0.91-2.59) or peptic ulcer-related bleeding (RR, 1.17; 95% CI, 0.622.21), although these results were compatible with chance. Conclusions: Calcium channel blocker use might be associated with an elevated risk of GI tract bleeding. These findings require confirmation in randomized studies.

Original languageEnglish (US)
Pages (from-to)1849-1855
Number of pages7
JournalArchives of Internal Medicine
Volume160
Issue number12
StatePublished - Jun 26 2000

Fingerprint

Calcium Channel Blockers
Gastrointestinal Tract
Hemorrhage
Confidence Intervals
Health Maintenance Organizations
Medical Records
Lower Gastrointestinal Tract
Blood Pressure
Upper Gastrointestinal Tract
Peptic Ulcer
Angiotensin-Converting Enzyme Inhibitors
Case-Control Studies
Heart Failure
Hypertension

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Kaplan, R. C., Heckbert, S. R., Koepsell, T. D., Rosendaal, F. R., & Psaty, B. M. (2000). Use of calcium channel blockers and risk of hospitalized gastrointestinal tract bleeding. Archives of Internal Medicine, 160(12), 1849-1855.

Use of calcium channel blockers and risk of hospitalized gastrointestinal tract bleeding. / Kaplan, Robert C.; Heckbert, Susan R.; Koepsell, Thomas D.; Rosendaal, Frits R.; Psaty, Bruce M.

In: Archives of Internal Medicine, Vol. 160, No. 12, 26.06.2000, p. 1849-1855.

Research output: Contribution to journalArticle

Kaplan, RC, Heckbert, SR, Koepsell, TD, Rosendaal, FR & Psaty, BM 2000, 'Use of calcium channel blockers and risk of hospitalized gastrointestinal tract bleeding', Archives of Internal Medicine, vol. 160, no. 12, pp. 1849-1855.
Kaplan RC, Heckbert SR, Koepsell TD, Rosendaal FR, Psaty BM. Use of calcium channel blockers and risk of hospitalized gastrointestinal tract bleeding. Archives of Internal Medicine. 2000 Jun 26;160(12):1849-1855.
Kaplan, Robert C. ; Heckbert, Susan R. ; Koepsell, Thomas D. ; Rosendaal, Frits R. ; Psaty, Bruce M. / Use of calcium channel blockers and risk of hospitalized gastrointestinal tract bleeding. In: Archives of Internal Medicine. 2000 ; Vol. 160, No. 12. pp. 1849-1855.
@article{415d101d0dce4c0c9e36478d90e15c65,
title = "Use of calcium channel blockers and risk of hospitalized gastrointestinal tract bleeding",
abstract = "Background: We conducted a case-control study of the association between calcium channel blocker use and gastrointestinal (GI) tract bleeding in hypertensive members of a health maintenance organization. Methods: Case patients (n = 174) were treated hypertensive health maintenance organization members hospitalized for GI tract bleeding between January 1992 and December 1994. Case patients were identified using computerized diagnosis codes and were confirmed by medical record review. Control subjects (n = 771) were treated hypertensive members selected from ongoing studies at the health maintenance organization. Computerized pharmacy data and medical records were used to assess medication use and other risk factors for GI tract bleeding. Results: Compared with β-blocker users, calcium channel blocker users had an age-, sex- and calendar year adjusted relative risk (RR) of GI tract bleeding of 2.60 (95{\%} confidence interval [CI], 1.71-3.96). The RR associated with calcium channel-blocker use was 2.05 (95{\%} CI, 1.33-3.17) after further adjustment for number of recent visits, diastolic blood pressure, chronic congestive heart failure, and duration of hypertension. No significant dose- response relationship was observed. Compared with β-blocker users, angiotensin-converting enzyme inhibitor users had an RR of 1.22 (95{\%} CI, 0.75-1.97). Calcium channel blocker use tended to be more strongly associated with risk of lower GI tract bleeding (RR, 2.56; 95{\%} CI, 1.08-6.05) than with risk of upper GI tract bleeding (RR, 1.54; 95{\%} CI, 0.91-2.59) or peptic ulcer-related bleeding (RR, 1.17; 95{\%} CI, 0.622.21), although these results were compatible with chance. Conclusions: Calcium channel blocker use might be associated with an elevated risk of GI tract bleeding. These findings require confirmation in randomized studies.",
author = "Kaplan, {Robert C.} and Heckbert, {Susan R.} and Koepsell, {Thomas D.} and Rosendaal, {Frits R.} and Psaty, {Bruce M.}",
year = "2000",
month = "6",
day = "26",
language = "English (US)",
volume = "160",
pages = "1849--1855",
journal = "JAMA Internal Medicine",
issn = "2168-6106",
publisher = "American Medical Association",
number = "12",

}

TY - JOUR

T1 - Use of calcium channel blockers and risk of hospitalized gastrointestinal tract bleeding

AU - Kaplan, Robert C.

AU - Heckbert, Susan R.

AU - Koepsell, Thomas D.

AU - Rosendaal, Frits R.

AU - Psaty, Bruce M.

PY - 2000/6/26

Y1 - 2000/6/26

N2 - Background: We conducted a case-control study of the association between calcium channel blocker use and gastrointestinal (GI) tract bleeding in hypertensive members of a health maintenance organization. Methods: Case patients (n = 174) were treated hypertensive health maintenance organization members hospitalized for GI tract bleeding between January 1992 and December 1994. Case patients were identified using computerized diagnosis codes and were confirmed by medical record review. Control subjects (n = 771) were treated hypertensive members selected from ongoing studies at the health maintenance organization. Computerized pharmacy data and medical records were used to assess medication use and other risk factors for GI tract bleeding. Results: Compared with β-blocker users, calcium channel blocker users had an age-, sex- and calendar year adjusted relative risk (RR) of GI tract bleeding of 2.60 (95% confidence interval [CI], 1.71-3.96). The RR associated with calcium channel-blocker use was 2.05 (95% CI, 1.33-3.17) after further adjustment for number of recent visits, diastolic blood pressure, chronic congestive heart failure, and duration of hypertension. No significant dose- response relationship was observed. Compared with β-blocker users, angiotensin-converting enzyme inhibitor users had an RR of 1.22 (95% CI, 0.75-1.97). Calcium channel blocker use tended to be more strongly associated with risk of lower GI tract bleeding (RR, 2.56; 95% CI, 1.08-6.05) than with risk of upper GI tract bleeding (RR, 1.54; 95% CI, 0.91-2.59) or peptic ulcer-related bleeding (RR, 1.17; 95% CI, 0.622.21), although these results were compatible with chance. Conclusions: Calcium channel blocker use might be associated with an elevated risk of GI tract bleeding. These findings require confirmation in randomized studies.

AB - Background: We conducted a case-control study of the association between calcium channel blocker use and gastrointestinal (GI) tract bleeding in hypertensive members of a health maintenance organization. Methods: Case patients (n = 174) were treated hypertensive health maintenance organization members hospitalized for GI tract bleeding between January 1992 and December 1994. Case patients were identified using computerized diagnosis codes and were confirmed by medical record review. Control subjects (n = 771) were treated hypertensive members selected from ongoing studies at the health maintenance organization. Computerized pharmacy data and medical records were used to assess medication use and other risk factors for GI tract bleeding. Results: Compared with β-blocker users, calcium channel blocker users had an age-, sex- and calendar year adjusted relative risk (RR) of GI tract bleeding of 2.60 (95% confidence interval [CI], 1.71-3.96). The RR associated with calcium channel-blocker use was 2.05 (95% CI, 1.33-3.17) after further adjustment for number of recent visits, diastolic blood pressure, chronic congestive heart failure, and duration of hypertension. No significant dose- response relationship was observed. Compared with β-blocker users, angiotensin-converting enzyme inhibitor users had an RR of 1.22 (95% CI, 0.75-1.97). Calcium channel blocker use tended to be more strongly associated with risk of lower GI tract bleeding (RR, 2.56; 95% CI, 1.08-6.05) than with risk of upper GI tract bleeding (RR, 1.54; 95% CI, 0.91-2.59) or peptic ulcer-related bleeding (RR, 1.17; 95% CI, 0.622.21), although these results were compatible with chance. Conclusions: Calcium channel blocker use might be associated with an elevated risk of GI tract bleeding. These findings require confirmation in randomized studies.

UR - http://www.scopus.com/inward/record.url?scp=0034717654&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034717654&partnerID=8YFLogxK

M3 - Article

VL - 160

SP - 1849

EP - 1855

JO - JAMA Internal Medicine

JF - JAMA Internal Medicine

SN - 2168-6106

IS - 12

ER -